FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, pharmacology, pharmaceutics and describes methods and compositions for treating and/or preventing hyperuricemia (HU) or metabolic disorders associated with HU. Such disorders include: acute or chronic gout, its sudden aggravations, gouty arthritis, urate nephrolithiasis, gouty nephropathy. Methods involve administering of therapeutically effective amount of diacerein, rhein or their pharmaceutically acceptable salt, analogue, prodrug or active metabolite. Wherein said compound reduces blood uric acid levels. Therapeutically effective amount of compound can be equivalent to 10-200 mg of diacerein base a day. Methods of treating with said compounds can be used in patients with poor tolerance to anti-inflammatory or urate-lowering agents.
EFFECT: group of inventions provides advantages in reducing or preventing HU due to ability of diacerein and its said analogues, salt, prodrug, active metabolite, even in form of single agent therapy to reduce blood uric acid level to normal and below, causing no side effects, refractory to therapy as compared with previously known agents against HU.
22 cl, 2 dwg, 2 ex, 2 tbl
Title |
Year |
Author |
Number |
MEDICINES CONTAINING DIACEREIN, AND METHODS FOR REDUCING URIC ACID LEVELS IN BLOOD WITH USING THEREOF |
2015 |
- Braun Z Karl Oskar
- Lim Khanpin
- Lyu Vei-Shu
- Chun Ten-Kuen
- Chen Chi-Kuan
|
RU2690372C2 |
USING IL-1 ANTAGONISTS FOR TREATING GOUT |
2007 |
- Vikehri Kehtrin
- Mellis Skott
|
RU2450824C2 |
COMBINED USE OF COMPOUND A AND COMPOUND B FOR PRODUCTION OF DRUGS FOR TREATMENT OF GOUT OR HYPERURICEMIA |
2019 |
- Chen, Tszyanven
- Shen, Yan
- Nin, Zhuj
|
RU2783862C1 |
METHODS FOR PRESERVING RENAL FUNCTION WITH USING XANTHINE OXIDOREDUCTASE |
2007 |
- Lademakher Kristofer
- Makdonal'D Patrisija
|
RU2508099C2 |
METHODS OF DIACEREIN APPLICATION IN ADDITIONAL TREATMENT OF DIABETES |
2011 |
- Ku Mannching Sherri
- Gao Dan'Chehn'
- Lu Vehj-Shu
- Chehn' Chikh-Min
- Lin' I-In'
|
RU2563988C2 |
THERAPEUTIC OR PREVENTIVE AGENT FOR TUMOUR LYSIS SYNDROME |
2013 |
- Ueda Takanori
- Yamauti Takakhiro
- Morita Mikhoko
- Khoriuti Khideki
|
RU2627591C2 |
DIACEREIN OR ANALOGUES THEREOF FOR INHIBITING ASC EXPRESSION, NLRP3 EXPRESSION AND/OR COMPLEXING OF NLRP3 INFLAMMASOMES |
2016 |
- Brown Iii, Carl Oscar
- Chen Chih-Kuang
- Lee Jing-Yi
- Lu Wei-Shu
|
RU2729066C2 |
METHODS AND SETS FOR PREDICTING RISK OF INFUSION RESPONSES AND ANTIBODY-MEDIATED LOSS OF RESPONSE IN THERAPY WITH PEGYLATED URICASE BY MONITORING URIC ACID CONTENT IN BLOOD SERUM |
2010 |
- Rozario-Dzhensen Tereza
- Rajt Dehvid Ehrik
|
RU2535038C2 |
COMPOSITIONS AND DOSES OF PEGYLATED URICASE |
2020 |
- Dzhonston, Llojd
- Kisimoto, Takasi, Kei
- Sendz, Erl
- Kotrilz, Verner
|
RU2831122C2 |
NOVEL SALT AND MEDICAL APPLICATION |
2012 |
- Ali Zakhid
- Batcher Kennet Dzhon
- Batt Richard Filip
- Felsted Stefan Dzhon
- Glett Sofi
- Makkernan Rat Mitchell
- Pejnser Mejninder
|
RU2609011C2 |